BRAF V600K mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-BRAF-V600K |
|---|---|
| Type | Biomarker |
| Aliases | BRAF V600KМутація BRAF V600K |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MELANOMA-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "15", "functional_impact": "activating (constitutive RAF-MEK-ERK signalling, like V600E)", "gene": "BRAF", "hgvs_protein": "p.V600K", "variant_type": "missense"} |
| Measurement | MethodTumor-tissue NGS panel (PCR may detect specifically; sequence-confirmation preferred) |
| Actionability lookup | {"gene": "BRAF", "variant": "V600K"} |
| Related biomarkers | BIO-BRAF-V600E |
Notes
~10-20% of BRAF V600 family in melanoma (V600E ~70-80%; V600K next most common; V600D/R/M rare). Encorafenib + binimetinib (COLUMBUS), dabrafenib + trametinib (COMBI-d/COMBI-v), vemurafenib + cobimetinib (coBRIM) all active. Slightly worse PFS vs V600E in some sub-analyses but doublet remains standard. ICI (nivo+ipi, anti-PD-1) equally effective; sequencing decision driven by tempo, brain mets, LDH.
Used By
Biomarker
BIO-BRAF-CLASS-II-III- BRAF non-V600 mutation (Class II / Class III)